PUBLISHER: Allied Market Research | PRODUCT CODE: 1139895
PUBLISHER: Allied Market Research | PRODUCT CODE: 1139895
The global human papillomavirus vaccine market size was valued at $3,892.7 million in 2021 and is projected to reach $10,823.0 million by 2030, growing at a CAGR of 12.4% from 2022 to 2030.
As the prevalence of human papillomavirus diseases grows, so does the market for human papillomavirus vaccines. The development of new HPV vaccines, as well as increased initiatives by government and commercial organizations for early screening and vaccination, are propelling the human papillomavirus (HPV) vaccine market forward. The rising incidence of HPV-related malignancies in the anal, oropharynx, and genital regions, as well as increased demand for HPV vaccinations to help decrease infections, are expected to keep the market growing steadily in the coming years.
Healthcare expenditures, on the other hand, are skyrocketing, with the drive toward prevention. Vaccination costs have risen from the single digits to triple digits several times over the last two decades, posing considerable issues for doctors and their patients while also putting a strain on public health funding.
The global human papillomavirus vaccine market trends is segmented on the basis of type, disease indication, industry vertical and region. Based on type, the market has been divided into tetravalent, nonavalent, and bivalent. Based on disease indication, the market has been divided into cervical cancer, anal cancer, vulvar & vaginal cancer, penile cancer, oropharyngeal cancer, and others. Based on industry vertical, the market has been divided into public and private alliances, government entities, physicians, and others. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The key players profiled in this report include: GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co., Inc., AstraZeneca Plc, Sanofi S.A., Novartis AG, Serum Institute of India Pvt. Ltd., Bharat Biotech, Inovio Pharmaceuticals, Inc and Xenetic Biosciences, Inc. among others.
Key Market Segments
By Type
By Disease Indication
By Industry Vertical
By Region